Shattuck Labs Inc
NASDAQ:STTK

Watchlist Manager
Shattuck Labs Inc Logo
Shattuck Labs Inc
NASDAQ:STTK
Watchlist
Price: 1.005 USD -0.5% Market Closed
Market Cap: 48m USD
Have any thoughts about
Shattuck Labs Inc?
Write Note

Shattuck Labs Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shattuck Labs Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Shattuck Labs Inc
NASDAQ:STTK
Stock-Based Compensation
$6.9m
CAGR 3-Years
76%
CAGR 5-Years
75%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shattuck Labs Inc
Glance View

Market Cap
48m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
1.148 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Shattuck Labs Inc's Stock-Based Compensation?
Stock-Based Compensation
6.9m USD

Based on the financial report for Dec 31, 2023, Shattuck Labs Inc's Stock-Based Compensation amounts to 6.9m USD.

What is Shattuck Labs Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
75%

Over the last year, the Stock-Based Compensation growth was 7%. The average annual Stock-Based Compensation growth rates for Shattuck Labs Inc have been 76% over the past three years , 75% over the past five years .

Back to Top